About Remedy Biologics
Based in Dublin, RemedyBio is a nano scale biotechnology company pioneering ultra high throughput therapeutic and diagnostic discovery. The company’s discovery technology massively improves the speed and scale of single cell analysis, with next-generation applications in immuno-oncology, autoimmune disease, and infectious disease.
Deep analysis of individual cell function of 10M-1Bn individual living cells
Very large scale, cell by cell combinational biology studying healthy tissue, disease biology, and immune function simultaneously
Disease characterisation based on statistical and machine analysis across millions or billions of cell results – for example from patient tumour biopsies
Sequencing, replication or banking of post-assay biology for therapeutic design or long term asset building
He serves on the board of the AMBER Centre for Advanced Materials and Bioengineering Research headquartered at Trinity College Dublin. Dan holds a BA and MSc from Trinity College Dublin, a PDip from Oxford University, received his MBA from Cornell where he was an Angear Merit Scholar, and is a Kauffman Fellow.
Paul holds a B.Sc. in Biotechnology and a Ph.D in Applied Immunology from Dublin City University and is a certified Lean Six Sigma Green Belt.
Colm holds medical and MSc degrees from Trinity, as well as an MBA from UCD’s Smurfit Business School. He is a Fellow of the Faculty of Pharmaceutical Medicine (RCP UK). Colm is an active member of PKU Ireland and a former IPPOSI board member.
Isabel holds a PhD in Diagnostics and Therapeutics from the Royal College of Surgeons in Ireland, a B.A. (Mod) in Biochemistry by Trinity College Dublin and studied Chemical Engineering at the University of Valladolid in Spain.
Recent News & Insights
Get infrequent updates from the Remedy Biologics team about upcoming projects and announcements.